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Platelet-rich plasma (PRP) is an autologous concentrated cocktail of growth factors and inflammatory mediators,
and has been considered to be potentially effective for cartilage repair. In addition, the fibrinogen in PRP may be
activated to form a fibrin matrix to fill cartilage lesions, fulfilling the initial requirements of physiological wound
healing. The anabolic, anti-inflammatory and scaffolding effects of PRP based on laboratory investigations, animal
studies, and clinical trials are reviewed here. In vitro, PRP is found to stimulate cell proliferation and cartilaginous
matrix production by chondrocytes and adult mesenchymal stem cells (MSCs), enhance matrix secretion by synoviocytes,
mitigate IL-1β-induced inflammation, and provide a favorable substrate for MSCs. In preclinical studies, PRP has been
used either as a gel to fill cartilage defects with variable results, or to slow the progression of arthritis in animal models
with positive outcomes. Findings from current clinical trials suggest that PRP may have the potential to fill cartilage
defects to enhance cartilage repair, attenuate symptoms of osteoarthritis and improve joint function, with an
acceptable safety profile. Although current evidence appears to favor PRP over hyaluronan for the treatment of
osteoarthritis, the efficacy of PRP therapy remains unpredictable owing to the highly heterogeneous nature of
reported studies and the variable composition of the PRP preparations. Future studies are critical to elucidate the
functional activity of individual PRP components in modulating specific pathogenic mechanisms.Introduction
Cartilage injuries are a common clinical challenge and
affect 27 million people in the United States, resulting in
208,600 primary total hip replacement and 450,000 primary
total knee replacements, according to data for 2005 [1,2].
The number of total hip replacement and total knee
replacement operations is expected to reach 572,000
and 3,480,000, respectively, by 2030 [1].
In the past decade, platelet-rich plasma (PRP) has
emerged as a non-operative treatment modality for car-
tilage injuries [3,4]. The rationale for its use is largely
dependent on its functional components (Figure 1).
While there are significant variations in its makeup, the
initial PRP consistently contains highly concentrated
platelets and a number of plasma proteins associated
with platelets during its preparation by centrifugation.
Platelets are produced by megakaryocytes as anu-
cleated cells [5]. A variety of growth factors, coagulation* Correspondence: rst13@pitt.edu
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2014factors, adhesion molecules, cytokines, chemokines and
integrins are stored in platelets [6-8]. After activation,
the platelets in PRP can release a multitude of growth
factors at concentrations significantly higher than the
baseline blood levels, including transforming growth
factor-β, platelet-derived growth factor (PDGF), insulin-
like growth factor (IGF), basic fibroblast growth factors,
vascular endothelial growth factor (VEGF), epidermal
growth factors, and many others [9]. Many of these ana-
bolic cytokines, such as transforming growth factor-β,
IGF, basic fibroblast growth factor and PDGF, are
chondro-promoting and chondro-protective [10-13].
Specifically, they can stimulate chondrocyte and multi-
potent mesenchymal stem cell (MSC) proliferation, pro-
mote chondrocyte synthesis of aggrecan and collagen
type II (Col II), drive MSC chondrogenic differentiation,
prevent chondrocyte and MSC apoptosis, and diminish
the catabolic effects of inflammatory cytokines, such as
IL-1β, and matrix metalloproteinases (MMPs).
Platelets in PRP are also a source of inflammatory media-
tors and modulators. After incubation with polyacrylamide
beads, platelets may release numerous anti-inflammatory
cytokines, including IL-1 receptor antagonist (IL-1ra),. The licensee has exclusive rights to distribute this article, in any medium, for 6
e, the article is available under the terms of the Creative Commons Attribution
by/2.0), which permits unrestricted use, distribution, and reproduction in any
ly cited.
Figure 1 Principal components and potential effects and actions
of PRP. PRP contains growth factors that stimulate cellular anabolism,
inflammatory mediators and modulators that exert anti-inflammatory
effects, and fibrinogen that acts as a biomaterial scaffold. PRP,
platelet-rich plasma.
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I and II, IL-4, IL-10, IL-13, and interferon γ [14]. Specif-
ically, IL-1ra inhibits the bioactivity of IL-1 by blocking
its receptors [15,16]. sTNF-RI and sTNF-RII can bind to
free TNFα, thereby preventing signal transduction
[15,16]. IL-4, IL-10 and IL-13 can increase IL-1ra pro-
duction and reduce TNFα-induced prostaglandin E2
production [17,18]. Interferon γ induces the production
of IL-18-binding protein, a natural inhibitor of IL-18
[19]. Although PRP also releases pro-inflammatory cy-
tokines, such as IL-1α, IL-1β, TNFα, IL-6, IL-8, IL-17
and IL-18, their concentrations are much lower than
those of the anti-inflammatory counterparts [14]. For
instance, the concentration of IL-1ra is over 23,000 times
higher than that of IL-1α and over 8,000 times than that
of IL-1β in PRP. The significant difference between the
concentrations of anti-inflammatory cytokines and those
of the pro-inflammatory factors in PRP suggests that PRP
may suppress inflammation in osteoarthritis (OA), thereby
protecting cartilage and reducing pain.
PRP also contains a variety of plasma proteins, which
are known to be critical components in the healing
mechanism of connective tissues [20]. Different from
serum, plasma contains fibrinogen and other clotting
factors, which can be activated to form a provisional fi-
brin scaffold for cells to adhere, migrate and proliferate
[21]. Since platelets aggregate along the fibrin fibers dur-
ing clotting, the resultant three-dimensional scaffold can
also act as a reservoir of growth factors that exert favor-
able effects on cells [21,22]. The clinical benefits of the
PRP fibrin matrix have been well-known in maxillofacial
surgery and chronic wound repair [23,24]. As articular
cartilage contains no blood vessels and is thus unable to
initiate the same healing process as other tissues with
good regenerative potential, the introduction of the PRPscaffold may mimic the initial stage of wound healing
and tissue repair.
Based on the potential benefits of its component bio-
logical factors, it has been hypothesized that PRP or its
derivatives may have positive effects on cartilage repair.
Since there are extensive reviews on specific growth
factors in the literature [25-27], this review will focus
mainly on the collective effects of PRP on cells, in-
cluding chondrocytes, MSCs from various tissue origins,
and synoviocytes, and on cartilage injury in laboratory
animal models, including equines, and human cartilage
diseases. In order to provide an accurate overview, the
classification system advocated by Dohan and colleagues
[28] is adopted here to categorize generic PRP into pure
PRP (P-PRP), leukocyte- and PRP (L-PRP), pure platelet-
rich fibrin, and leukocyte- and PRF (L-PRF), whenever
relevant information is available.
Effect of platelet-rich plasma on cells
Chondrocytes
Proliferation
In almost all published studies, PRP has been shown to
have a strong positive effect on chondrocyte prolifera-
tion in vitro (Table 1) [29-34]. When adult porcine
chondrocytes were cultured in alginate beads in the
presence of 10% PRP releasate (PRPr), 10% platelet-poor
plasma (PPP) releasate or 10% fetal bovine serum (FBS)
for 72 hours, the increase in DNA content in the PRP
group was significantly higher than that in the PPP
group and that in the FBS group [29]. The stimulatory
effect of PRP on chondrocyte proliferation was also ob-
served after 4, 8 and 12 days of in vitro culture, in either
a monolayer or three-dimensional environment [30].
Additional studies revealed a dose- and time-dependent
enhancement of chondrocyte proliferation by PRPr, even
during the 20 day monolayer culture [31,32].
Differentiation
There is, however, less concordance in the effect of PRP
on chondrocyte differentiation. Akeda and colleagues
[29] reported that 10% PRP treatment significantly in-
creased proteoglycan and Col II synthesis compared to
treatments with 10% PPP or 10% FBS, with the major
profiles of proteoglycan and collagens being similar to
those seen in cells cultured with FBS, indicating main-
tenance of a stable chondrocyte phenotype with PRP
exposure. Similar effects were also noted in human
osteoarthritic chondrocytes [30]. The supernatant from
platelet-rich fibrin (PRF) up-regulated the mRNA ex-
pression of Col II and aggrecan and increased synthesis
of glycosaminoglycan and proteoglycan by chondrocytes
cultured either on the two-dimensional surface of fibrin
scaffolds or in three-dimensional scaffolds compared to
controls without addition of exudate. Furthermore, a
Table 1 Summary of in vitro effects of platelet-rich plasma on chondrocytes
Cell type Intervention Outcome Reference
Porcine chondrocytes 10% PRP releasate after thrombin
and CaCl2 activation
Increased cell proliferation,
proteoglycan and Col II synthesis
[29]
Human osteoarthritic
chondrocytes
Bovine fibrin + L-PRF releasate on
two-dimensional surface and in
three-dimensional scaffold
Increased cell proliferation and Col II
and aggrecan mRNA expression and GAG
and proteoglycan accumulation
[30]
Human osteoarthritic
chondrocytes
5% PRP releasate obtained
by two cycles of freezing and thawing
Increased cell proliferation, proteoglycan synthesis,
Sox-9 and aggrecan mRNA expression and proteins
associated with chondrocyte differentiation
[31]
Bovine chondrocytes Platelet supernatant Stimulated proliferation, but failed to induce deposition
of typical cartilaginous ECM
[32]
Human chondrocytes 1% or 10% platelet supernatant
(leukocyte-filtered)
Accelerated cell expansion, but reduced Col II mRNA expression
and induced chondrocytes towards a fibroblast-like phenotype
[33]
Sheep chondrocytes Double-spun PRP activated by CaCl2 Stimulated cell proliferation, but reduced Col II mRNA
expression
[34]
Rabbit chondrocytes Hydrogel + chondrocytes with
double-spun PRP
Enhanced chondrogenic differentiation and maturation with
up-regulation of CB1 and CB2
[36,37]
Human osteoarthritis
chondrocytes
Gelatin microcarriers + biological glues
(whole blood, PPP, PRP, or commercial
fibrin glue)
No difference in ECM production between any two
of these groups
[38]
Human osteoarthritic
chondrocytes
10% L-PRP releasate
after CaCl2 activation
Decreased IL-1β-induced inflammatory effects and inhibited
NF-κB activation
[39]
Immortalized human
chondrocytes
PRP releasate activated by CaCl2 Decreased COX-2 expression and inhibited NF-κB activation
via HGF and TNF-α
[40]
Col, collagen; ECM, extracellular matrix; GAG, glycosaminoglycan; HGF, hepatocyte growth factor; L-PRF, leukocyte- and platelet-rich fibrin; L-PRP, leukocyte- and
platelet-rich plasma; NF-κB, nuclear factor kappa B; PPP, platelet-poor plasma; PRP, platelet-rich plasma.
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could also induce the expression of proteins associated
with chondrocyte differentiation [31]. In particular, PRPr
increased the expression of aggrecan and Sox9, without
increasing the expression of Col X and alkaline phosphat-
ase. Increased Sox9 expression has been shown to be asso-
ciated with the chondrocytic re-differentiation process
[35]. These results show that PRP had differential effects
on chondrocytes; that is, promoting the synthesis of hya-
line cartilage matrix while cellular progression to terminal
hypertrophy is not facilitated or at least delayed. Another
study further demonstrated that the chondrogenic differ-
entiation and maturation induced by PRP treatment was
related to the up-regulated expression of cannabinoid re-
ceptor 1 and 2 [36,37]. However, a few authors have ar-
gued that PRP treatment was unable to induce the
deposition of typical cartilage matrix components [32,34],
that there was no difference in the enhancement of extra-
cellular matrix (ECM) production between the groups
with PRP, PPP, whole blood or fibrin glue added into
gelatin-based microcarriers [38], and that PRP treatment
could in fact induce a dedifferentiation of chondrocytes
towards a fibroblast-like phenotype [33]. This lack of
consistency among the published reports may be attribut-
able to the heterogeneity of study designs, variations in
PRP preparations, and differences in PRP delivery. For in-
stance, some studies used platelet lysate through repeated
freeze-thawing after centrifugation, some employed theexudate after clot formation without addition of external
activators, while others adopted PRPr collected after
thrombin activation [29-31].
Anti-inflammation
PRP has also been demonstrated recently to have anti-
inflammation potential in an osteoarthritic milieu. Hu-
man osteoarthritic chondrocytes were cultured with
10 ng/ml IL-1β to mimic an osteoarthritic environment
[39] in medium with or without 10% PRPr. After
48 hours, IL-1β inhibited Col II and aggrecan gene ex-
pression and concomitantly increased expression of a
disintegrin and metalloproteinase with thrombospondin
motifs-4 and prostaglandin-endoperoxide synthase-2,
whereas PRPr supplementation reduced these IL-1β-
mediated effects. In addition, the IL-1β-induced activa-
tion of nuclear factor kappa B (NF-κB), a major pathway
involved in the pathogenesis of OA, could be com-
pletely inhibited by PRP (P < 0.001). Further study re-
vealed that PRPr inhibited NF-κB activation through
increasing gene expression of hepatocyte growth factor
(HGF) and TNF-α [40]. HGF has been shown to in-
crease NF-κB inhibitor-α expression, thus impairing
p65 translocation to the nucleus, which is necessary for
NF-κB activation [41,42]. TNF-α enhances p50 homodi-
mer formation and its binding to DNA to inhibit NF-κB
pathway activation [43]. It is noteworthy that the NF-κB
pathway is not the only one involved in the PRP anti-
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PRP could also suppress the activation of the Src/PI3K/
AKT pathway, thus inhibiting chondrocyte apoptosis
and inflammation induced by IL-1β [44].
It should also be noted that some PRP formulations
could be pro-inflammatory [45]. The presence of concen-
trated leukocytes increased the levels of catabolic and pro-
inflammatory signaling molecules, including MMPs and
IL-1β [46]. In addition, activated platelets could produce
IL-1β to mediate pro-inflammatory signaling [47]. However,
the most represented pro-inflammatory cytokine, IL-1β,
only showed a slight increase after platelet activation,
whereas the anti-inflammatory molecules, such as IL-4 and
IL-10, increased more than five times [40]. A recent study
confirmed the dual effect of platelet lysate on human chon-
drocytes - a transient pro-inflammatory activity followed by
an inflammation resolution [48]. Although the net results
of PRP are variable owing to compositional heterogeneity,
the anti-inflammatory effect is likely to predominate in
PRP formulations in which the presence of leukocytes is
substantially reduced.
Adult mesenchymal stem cells
As candidate cells applicable for tissue engineering-based
approaches to cartilage repair, MSCs have noticeable
advantages over chondrocytes due to their abundant
availability, robust chondrogenic activity accompanied
by cartilage matrix production, and multi-lineage differ-
entiation ability to repair osteochondral defects [49-51].
Bone marrow-derived mesenchymal stem cells
Among their various tissue sources, MSCs derived from
bone marrow (BMSCs) are employed most extensively
in cartilage engineering. Many researchers have found
that PRP exhibits a mitogenic effect on MSCs (Table 2)
[34,52-55]. When human BMSCs in monolayer were
cultured with 10% inactivated autologous PRP, a five-
fold increase in cellular proliferation was seen at day 7Table 2 Summary of effects of platelet-rich plasma on mesen
Cell type Intervention Outc
Sheep BMSCs Double-spun PRP activated
by CaCl2
Incre
and C
Human BMSCs 50% platelet lysate after two
cycles of freezing and thawing
Prom
chon
Human BMSCs 10% inactivated PRP (leukocyte
concentration unreported)
Enha
aggre
Rabbit BMSCs, ADSCs 10% double-spun inactivated PRP Incre
aggre
Mouse MDSCs Double-spun PRP Prom
and i
Human subchondral
progenitor cells
5% P-PRP after freezing
and thawing
Incre
but d
ADSC, adipose-derived mesenchymal stem cell; BMSC, bone marrow-derived mesen
P-PRP, pure platelet-rich plasma; PRP, platelet-rich plasma.relative to the control without PRP supplementation [56].
While both chondrogenic and osteogenic gene markers
were up-regulated in the presence of PRP, the chondro-
genic markers, including Sox9 and aggrecan, increased
much more (over 10-fold increase) than RUNX2 (less than
2-fold increase) [56], a marker of early osteogenic differen-
tiation [57]. The authors concluded that PRP could en-
hance the proliferation and chondrogenic differentiation
of BMSCs. In this study, however, BMSCs were cultured
for only 7 days, and the long-term effects of PRP on MSCs
thus remained unclear. In another study with 21 days of
BMSC culture, expression of Sox9, aggrecan and Col II in-
creased significantly at both the mRNA and protein levels
in the presence of inactivated PRP, compared to the FBS
control [21]. However, Col I gene and protein expression
was also increased concomitantly by PRP. This non-
selective up-regulation of both chondrogenic and osteo-
genic genes by PRP in multipotent BMSCs in vitro must
be considered with caution in cartilage tissue engineering,
but may be beneficial and applicable for repairing osteo-
chondral defects.
Adipose- and muscle-derived stem cells and human
subchondral bone-derived progenitor cells
Besides BMSCs, the effect of PRP on MSCs derived from
fat, muscle and subchondral bone has also been prelimin-
arily studied. Rabbit adipose-derived MSCs responded to
PRP stimulation in a manner similar to BMSCs, in that
cell proliferation, gene and protein expression of Sox9,
aggrecan, Col I and Col II were enhanced significantly
compared to the FBS controls [21]. When muscle-derived
MSCs were cultured in the presence of PRP, their ability
to proliferate, adhere and migrate was significantly pro-
moted [58]. Although chondrogenic gene expression was
not up-regulated, the number of cells producing Col II
was increased markedly. Meanwhile, cellular apoptosis
was also increased in vitro, but in vivo study yielded con-
trary results showing that apoptosis was suppressed in thechymal stem cells from various tissue sources in vitro
ome Reference
ased cell proliferation
ol II mRNA expression
[34]
oted proliferation and triggered
drogenic differentiation
[55]
nced cell proliferation and Sox9,
can and RUNX2 mRNA expression
[56]
ased cell proliferation and expression of Sox9,
can, Col II and Col I mRNA and proteins
[21]
oted cell proliferation, adhesion and migration of MDSCs,
ncreased number of cells producing Col II and cell apoptosis
[58]
ased cell migration and cartilaginous matrix formation,
id not affect osteogenic and adipogenic differentiation
[60]
chymal stem cell; Col, collagen; MDSC, muscle-derived mesenchymal stem cell;
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are considered the main cell sources responsible for the
repair of cartilage defects in the clinical procedure of
microfracture [59]. A study reported that P-PRP treatment
could stimulate the vertical migration of subchondral pro-
genitors and cartilaginous matrix accumulation, including
proteoglycan and Col II [60]. More importantly, while
chondrogenic differentiation of the progenitor cells was
induced significantly by PRP treatment, osteogenic and
adipogenic differentiation were not affected. These find-
ings suggest that PRP might accelerate the migration of
the subchondral progenitors to repair cartilage defects
with the formation of hyaline cartilage.
Scaffolding activity
In addition to the positive effects on MSC proliferation,
differentiation and migration, PRP may also provide a
three-dimensional substrate for cell seeding by virtue of
the presence of fibrinogen, which gives rise readily to fibrin
gel upon thrombin or calcium activation. In a recent study,
about 1 × 105 rabbit BMSCs were mixed with 60 μl ultra-
filtered platelet lysate and the composite was then activated
by thrombin and CaCl2 to form a three-dimensional
cell-laden scaffold, followed by in vitro culturing in
chondrogenic induction medium for 21 days [61]. At
1 week, round-shaped chondrocyte-like cells were found
homogeneously distributed inside lacunae and some cells
clustered together within the scaffold. Histological analysis
at 3 weeks further confirmed the presence of these
chondrocyte-like cells and the accumulation of cartilagin-
ous ECM deposition. However, the details of the structure
of this scaffold were not investigated.
In another study, Kang and colleagues [22] examined the
components and microstructure of L-PRF, which formed
naturally during the single step centrifugation of whole
blood without anti-coagulants. They found that there were
two distinct zones in the PRF scaffold, the platelet zone and
the fibrin zone. The marked advantage of L-PRF is the ease
of the procedure and the absence of additional chemicals.
Nonetheless, the PRF preparation may not allow cells to
seed evenly inside, and its two-zone microstructure implies
possible large variations in the release of growth factors.
In our recent study, we adopted the traditional double
spinning method to prepare liquid PRP first. Then MSCs
were distributed in the PRP before it was activated by CaCl2
to form a three-dimensional scaffold. Histological and scan-
ning electron microscopy evaluations revealed that the PRP
matrix had a honeycomb microstructure with platelets ag-
gregated along the fibrin skeleton to which MSCs adhered
(Figure 2) [21]. Another pilot study demonstrated that
equine BMSCs cultured in the three-dimensional PRP gel
for 3 weeks resulted in enhanced cell proliferation and pro-
teoglycan synthesis compared to those in the fibrin gel
alone [3]. Unlike L-PRF, however, both the platelet lysateand the double-spun PRP activated by CaCl2 usually have a
low density of fibrin and weak polymerization, and thus dis-
solve quickly, similar to fibrin glue.
It was reported that commercially available fibrin gel
would disintegrate within 7 days, but such a rapid deg-
radation could be delayed by seeding cells and adding fi-
brinolytic inhibitors, such as tranexamic acid, aprotonin,
and galardin [62-64]. PRP-tranexamic acid gel seeded
with chondrocytes could maintain stability in vitro for
4 weeks without any shrinkage, while cells remained vi-
able and were able to migrate [64]. The seeded chondro-
cytes likely produced abundant ECM, in a manner
commensurate with scaffold degradation [62]. Inhibition
of fibrin degradation would also mean slower and more
extended release of growth factors to produce better
reparative results [65]. The low mechanical property of
the PRP fibrin scaffold may be improved through geni-
pin cross-linking [66], ruthenium-catalyzed photo cross-
linking [67], or adjusting the content of fibrinogen [68].
An optimized fibrin gel could resist dynamic compression
and shear at the tissue site, while the embedded chondro-
cytes continued to produce a coherent cartilaginous ECM,
containing proteoglycan and Col II [66,68]. In addition,
PRP gel may also be employed with other biomaterials to
enhance its mechanical properties.
Synoviocytes
Intra-articular use of PRP may also have an effect on
fibroblast-like synoviocytes, which can secrete hyaluronic
acid (HA) and HGF and produce cytokines and MMPs
found in synovial fluid [69]. HA in the synovial fluid has
been shown to have beneficial effects for arthritic patients
[70], while HGF is involved in many signaling pathways
and has been shown to inhibit NF-κB activation [40]. On
the other hand, MMPs can mediate cartilage catabolism
[71]. The effect of PRP on synoviocytes may thus indir-
ectly affect the repair of cartilage injury. Synoviocytes from
OA patients cultured in 20% single-spun P-PRP activated
by CaCl2 produced significantly more HA and HGF com-
pared to those cultured in PPP [72]. P-PRP-enhanced HA
secretion was also observed in synoviocytes in the pres-
ence of IL-1β, indicating that PRP could enhance chon-
droprotection and joint lubrication via synoviocytes even
in the face of inflammation. L-PRP-treated human syno-
viocytes exhibited significantly higher levels of MMPs than
untreated synoviocytes [73], but P-PRP did not exacerbate
the IL-1β-induced rise of MMPs in synoviocytes from OA
patients [72].
Effect of platelet-rich plasma on cartilage repair
in animal models in vivo
Cartilage defect models
In order to investigate whether PRP has a positive effect
on chondrogenesis in vivo, Wu and colleagues [74]
Figure 2 Scanning electron microscopy of MSC-laden PRP scaffolds. MSCs adhere to the PRP fibrin fibers (adhesion sites indicated by arrows
in B). A) low magnification; B) high magnification. MSC, mesenchymal stem cell; PRP, platelet-rich plasma.
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to generate PRP/chondrocyte composites with a final cell
density of 5 × 107/ml. The composites were activated by
thrombin before they were injected into the dorsal sub-
cutaneous tissue of the donor rabbits. After 2 months, hard
palpable nodules were formed under the skin and magnetic
resonance imaging (MRI) evaluation demonstrated the
presence of cartilage-like tissue. Safranin-O staining and
Masson's trichrome histological staining indicated the
presence of proteoglycan and collagen. Although the type
of the newly regenerated collagen was not determined,
these findings suggested that PRP could be used as a cell
scaffold in cartilage tissue engineering (Table 3). In another
study, PRP was used as a bioactive scaffold alone or withTable 3 Summary of animal studies of platelet-rich plasma fo
Animal model Defect size Intervention
Rabbit osteochondral
defect in trochlea
4 mm diameter,
3 mm depth
Untreated; double-spun PRP activat
by CaCl2; PRP gel + ADSCs;
PRP gel + BMSCs
Rabbit osteochondral
defect in trochlea
5 mm diameter,
4 mm depth
Untreated; double-spun PRP
activated by thrombin and
CaCl2 + PLGA; PLGA
Rabbit osteochondral
defect in trochlea
4 mm diameter,
3 mm depth
Untreated; collagen scaffold alone
or with doule-spun inactivated PRP
Sheep osteochondral
defect in femoral
condyle
7 mm diameter,
9 mm depth
Untreated; collagen-hydroxyapatite
scaffold alone or with L-PRP
activated by CaCl2
Goat osteochondral
defect in trochlea
6 mm diameter,
0.8 mm depth
Engineered cartilage implants
with periosteal flap or L-PRP
or human fibrin
Sheep chondral
defect in femoral
condyle
8 mm diameter,
cartilage only
Microfracture alone or with
five weekly P-PRP intra-articular
injections
Sheep chondral
defect in femoral
condyle
8 mm diameter,
cartilage only
Microfracture alone, with single
P-PRP injection or with P-PRP
and fibrin gel filling up the defects
ADSC, adipose-derived mesenchymal stem cell; BMSC, bone marrow-derived mesen
leukocyte- and platelet-rich plasma; PLGA, poly (lactic-co-glycolic acid); P-PRP, pureMSCs to fill osteochondral defects (4 mm in diameter,
3 mm in depth) in the femoropatellar groove of rabbits
[21]. At 12 weeks post-implantation, PRP scaffold alone
yielded better macroscopic, histological and immunological
results than those in the untreated group, but worse than
those of the PRP-MSC group. Both immunohistological
and molecular evaluation demonstrated the presence of
Col II in the regenerated tissue in the PRP scaffold group
and more abundant Col II accumulation in the PRP-MSC
group. In light of the poor mechanical properties of PRP,
Sun and colleagues [75] used PRP as an additive to poly
(lactic-co-glycolic acid) (PLGA) scaffolds to repair large
osteochondral defects (5 mm in diameter, 4 mm in depth)
in rabbits. After 4 and 12 weeks, compared to PLGA alone,r treatment of cartilage defects
Outcome Reference
ed PRP group yielded better macroscopic
and histological results than untreated,
but worse than PRP with cells
[21]
Macroscopic examination, micro-CT,
and histology of newly formed
osteochondral tissue differed significantly
between PRP-treated and untreated groups
[75]
PRP-collagen group had highest histological
scores and most GAG content; mechanical property
was only better than that in the untreated group.
[76]
Good integration of the chondral surface in both
treatment groups; better osteochondral reconstruction
in the group treated with scaffold alone than with PRP
[77]
PRP and human fibrin glue interfered with retention
of the implants and integration with adjacent cartilage
[78]
PRP enhanced the macroscopic, histological and
biomechanical characteristics at 3 months, 6 months
and 12 months, but did not produce hyaline cartilage
[79]
PRP with fibrin gel yielded the best histological results
and biomechanical results, close to those of the normal
cartilage, but still did not produce hyaline cartilage
[80]
chymal stem cell; CT, computed tomography; GAG, glycosaminoglycan; L-PRP,
platelet-rich plasma; PRP, platelet-rich plasma.
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proved subchondral bone formation. These results were
consistent with those from a previous study that used
bilayer collagen scaffold with or without PRP to repair
osteochondral defects (4 mm in diameter, 3 mm in depth)
in rabbits [76].
However, the beneficial effect of PRP on cartilage regen-
eration in rabbits could not be consistently verified in lar-
ger animal models, including sheep and goats. In a sheep
model, osteochondral defects (7 mm in diameter, 9 mm in
depth) were created in the femoral condyles and then
filled with collagen-hydroxyapatite scaffold alone or in
combination with L-PRP [77]. Although good integration
of the chondral surface was achieved in both treatment
groups at 6 months, incomplete bone formation and ir-
regular cartilage surface integration were observed in the
PRP-treated group, whereas significantly better osteochon-
dral reconstruction was seen in the group treated with the
scaffold alone. Another study using a goat model of shal-
low osteochondral defects (6 mm in diameter, 0.8 mm in
depth) also confirmed the inhibitory effect of L-PRP
addition on cartilage repair [78]. Nonetheless, according
to the study by Milano and colleagues [79], repeated P-
PRP intra-articular injections in a sheep chondral model
(8 mm in diameter, cartilage only) significantly improved
the macroscopic, histological and biomechanical outcomes
of the newly regenerated tissue compared to the group
without PRP injections. In addition, the reparative re-
sponse after P-PRP injections was more durable and stable
during the 12-month observation period. Their later study
showed that stabilizing P-PRP in the chondral defects with
fibrin glue resulted in higher scores in histological and
mechanical assessment than PRP intra-articular injections,
but neither technique resulted in the regeneration of hya-
line cartilage [80]. These conflicting results suggest the
negative effect of concentrated leukocytes in PRP formula-
tions on cartilage repair.
Arthritis models
In a traumatic OA model in rabbits induced by unilateral
transection of the anterior cruciate ligament, 33 rabbits
were treated with phosphate buffered saline (PBS) injec-
tions, PBS-microsphere injections, injections of PRPr after
thrombin and CaCl2 activation, or injections of micro-
spheres containing PRPr into the affected knee joints; in-
jections were given twice with a 3-week interval between
them (Table 4) [65]. Ten weeks later, severe OA changes
(erosion to subchondral bone) were observed in 25% of the
PBS group, 33% of the PBS-microsphere group and 25% of
the PRPr group, but none of the joints in the PRPr-
microsphere groups showed severe OA. This finding sug-
gested that the sustained release of PRPr had an inhibitory
effect on the progression of traumatic OA. The effect of
PRP on existing advanced OA remains to be investigated.In a non-traumatic OA model in rabbits induced by twice
intra-articular injections of collagenase type II, single-spun
PRP was injected 4 weeks later, with saline infiltration as a
control [81]. Four weeks later, the PRP-injected knees
showed significantly reduced macroscopic and histologic
cartilage degeneration scores compared to the control, sug-
gesting that PRP could suppress the catabolic effect of col-
lagenase or enhance the anabolic response of the damaged
cartilage. However, neither of the above studies investi-
gated changes in the inflammatory mediators involved.
PRP has also been tested for the treatment of rheumatoid
arthritis of joints. In a pig model, bovine serum albumin
was administered to induce arthritis in bilateral knees [82].
Autologous PRP was injected into the right knees 2 weeks
and 4 weeks later, with saline injections into the left knees
as the control group. At 2 weeks after the second injection,
PRP treatment significantly attenuated the decrease in pro-
teoglycan and Col II contents in cartilage, the increase in
IL-6 and VEGF levels, and the elevation in protein concen-
trations of IL-1β, IL-6, VEGF, and IGF-1 in synovium and
cartilage, compared to the control. These results not only
showed that PRP might be an alternative treatment for
acute rheumatoid arthritis, but also supported the notion
that PRP had anti-inflammatory effects on joint arthritis.
Equine arthritis
One key limitation of the current arthritis models is that
the cartilage pathology is created artificially rather than
from natural diseases, which may undermine the justifi-
cation of the clinical application of PRP. In a report by
Carmona and colleagues [83], seven horses suffering se-
vere joint diseases (four with OA, three with osteochon-
drosis) were treated with a cycle of three intra-articular
injections of PRP at 2-week intervals after other conser-
vative methods or arthroscopic interventions failed. Two
months after the last injection, the synovial effusion and
the degree of lameness in all seven horses were signifi-
cantly reduced (P < 0.05), and the trend of symptomatic
relief continued during the 1 year follow-up. In this study,
however, cartilage changes were not monitored.
Effect of platelet-rich plasma on human cartilage
injury
On the basis of the strength of evidence, current pub-
lished reports of PRP treatment of degenerative cartilage
diseases may be divided into the following four levels:
level IV, case series; level III, retrospective comparative
studies; level II, prospective comparative studies or lesser
quality randomized control trials (RCTs); and level I,
high-quality RCTs [84,85].
Focal cartilage lesions
Only a few reports on PRP treatment of focal cartilage de-
fects have been published, all of which are case reports
Table 4 Summary of animal studies of platelet-rich plasma for treatment of knee arthritis
Model or disease Intervention Outcome Reference
Traumatic OA model in
rabbits induced by ACLT
Injections of PBS, PBS-microspheres,
PRPr after thrombin and CaCl2 activation
or PRPr-microspheres
OA occurred in 25% of the PBS group, 33% of
the PBS-microsphere group, and 25% of the PRP group,
but no joints in the PRP-microsphere group showed
OA changes at 10 weeks
[65]
Non-traumatic OA model
in rabbits induced by
collagenase
P-PRP or saline intra-articular injection
at 4 weeks after collagenase infiltration
Significantly lower macroscopic and microscopic scores
in the PRP-treated group than in the saline-treated group
at 8 weeks
[81]
BSA-induced rheumatoid
arthritis model in pigs
Double-spun, inactivated PRP intra-articular
injections or saline at 2 weeks and 4 weeks
after BSA injection
PRP suppressed the decrease of proteoglycan and
Col II content in cartilage and the increase of inflammatory
cytokines in synovium and cartilage induced by BSA at 6 weeks
[82]
Primary OA or
osteochondrosis in horses
Three P-PRP intra-articular injections
at 2 week intervals
PRP diminished synovial effusion and lameness
in the affected joints significantly during 1 year follow-up
[83]
ACLT, anterior cruciate ligament transection; BSA, bovine serum albumin; Col, collagen; OA, osteoarthritis; PBS, phosphate buffered saline; P-PRP, pure platelet-rich
plasma; PRP, platelet-rich plasma; PRPr, PRP releasate.
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(Table 5). Thus, only low levels of evidence are provided.
One case report described a 12-year-old soccer player
who was diagnosed with a large (>2 cm2), loose chondral
body avulsed from the medial femoral condyle [86]. After
the loose body was placed in its bed, CaCl2-activated P-
PRP was injected to fill up any mismatch between the
crater and the fragment during arthroscopic surgery.
Given the extremely poor prognosis of the larger chondral
avulsion, which did not extend into the vascularizedTable 5 Summary of clinical studies of platelet-rich plasma fo
Patient number
(age/range)
Defect position Lesion size or
grade
Innervation
1 (12 years) Medial femoral
condyle
>2 cm2
full-thickness
avulsion
Reattachment of lo
body and P-PRP in
5 (21–37 years) Femoral condyle 3-12 cm2,
full-thickness
Cultured autologo
BMSC+ platelet-ric
fibrin glue
5 (24–45 years) Patellar cartilage 1-3 cm2; ICRS
grade III or IV
Col I/III scaffold w
L-PRP gel
20 (15–50 years) Knee osteochondral
lesions
ICRS grade III
or IV
HA membrane + B
concentrate + P-PR
48 (15–50 years) Talar osteochondral
lesions
1.6-2.6 cm2;
3–5 mm deep
Collagen or HA
membrane +
BM concentrate +
P-PRP gel
52 (25–65 years) Femoral and tibial
condyle
1.5-5 cm2;
Outerbridge III
or IV
PGA-HA scaffold
immersed in P-PRP
and BM stimulatio
AOFAS, American Orthopaedic Foot and Ankle Society; BM, bone marrow; BMSC, bo
ICRS, International Cartilage Repair Society; IKDC, International Knee Documentation
leukocyte- and platelet-rich plasma; MRI, magnetic resonance imaging; P-PRP, puresubchondral bone, this treatment was considered very
successful, as the patient returned to soccer competition
without any symptoms by 38 weeks postoperatively. The
authors attributed the success to the addition of PRP,
which augmented the reattachment of the cartilage
fragment.
As MSCs play a crucial role in cartilage tissue engin-
eering, Haleem and colleagues [87] seeded expanded
autologous BMSCs into PRP gel to fill full-thickness car-
tilage defects in femoral condyles. Five patients aged 21r treatment of focal cartilage defects
Follow-up
(months)
Outcome Reference
ose
jection
9 Complete reattachment and
perfect continuity on MRI at
18 weeks; return to soccer training
at 18 weeks and fully involved in
competition at 9 months
[86]
us
h
14.2 All patients symptoms improved;
ICRS nearly normal in 2 patients;
MRI showed complete defect fill
in 3 patients
[87]
ith 24 VAS pain scores were reduced and
function improved, but intralesional
osteophytes in 3 patients and irregular
surface were found in all
[88]
M
P gel
29 IKDC improved from 32.9 to 90.4;
KOOS from 47.1 to 93.3; Col II positive
and Col I negative staining in entire
biopsies in 2 patients
[89]
29 AOFAS improved from 64.4 to 91.4;
94% return to low-impact sports at
4.4 months; varying regeneration on
MRI and histological exam
[90]
n
12 All KOOS subscores improved;
nearly normal appearance in 10
during arthroscopy; hyaline-like
cartilage formation in 5 biopsies
[91]
ne marrow-derived mesenchymal stem cell; Col, collagen; HA, hyaluronic acid;
Committee; KOOS, Knee injury and Osteoarthritis Outcome Score; L-PRP,
platelet-rich plasma; PGA, polyglycolic acid; VAS, visual analogue scale.
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from 3 to 12 cm2. All patients’ symptoms improved over
the follow-up period of 12 months. Average Lysholm
and Revised Hospital for Special Surgery Knee scores
showed statistically significant improvement (P < 0.05).
Arthroscopic scores recommended by the International
Cartilage Repair Society were nearly normal in two pa-
tients who consented to a second-look arthroscopy. MRI
of three patients revealed complete defect fill and sur-
face congruity with native cartilage.
Considering the potential risks of culturing BMSCs
in vitro, a few authors have been inclined to adopt micro-
fracture or bone marrow concentrate to introduce BMSCs
into the defects. Dhollander and colleagues reported on five
patients who were treated with microfracture and L-PRP
gel filling up the patellar cartilage defects ranging from 1
to 3 cm2 [88]. The defects were sealed with Col I/III mem-
branes. Symptoms and knee function of all five patients
improved markedly after operation. However, such favor-
able results were not reflected by the MRI data, which
showed subchondral lamina and bone changes in all five
cases, and intralesional osteophytes in three at 2 year
follow-up. In another case series of 20 patients, a com-
posite of HA membrane, bone marrow concentrate and
P-PRP gel was implanted into the osteochondral defects in
the femoral condyle [89]. During the 29-month follow-up,
the International Knee Documentation Committee (IKDC)
scores improved from 32.9 to 90.4 (P < 0.0005), and the
Knee injury and Osteoarthritis Outcome Scores (KOOS)
improved from 47.1 to 93.3 (P < 0.0005). In two pa-
tients, who consented to a biopsy at 12 months post-
operatively, cells were found to be homogeneously
distributed, and were stained positively for Col II but
negatively for Col I throughout the entire thickness of
the biopsies, indicating the high quality of the regener-
ated cartilage. Another report confirmed the effective-
ness of such a one-step repair of talar cartilage defects
in 48 cases [90]. After implantation, the mean American
Orthopaedic Foot and Ankle Society (AOFAS) scores
improved steadily, from a pre-operative value of 64.4 to
83.3 at 6 months, 88.9 at 12 months, and 91.4 at
24 months. Among the 48 patients, 45 (94%) could par-
ticipate in low-impact sports at a mean of 4.4 months,
and 37 (77%) could participate in high-impact sports at
a mean of 11.3 months.
Given the poor mechanical properties of the PRP gel,
Siclari and colleagues [91] adopted polyglycolic acid-HA
scaffolds immersed in autologous P-PRP to fill knee
cartilage defects. At 9 months, all KOOS subscores
improved in 52 patients, including pain, symptoms, ac-
tivities of daily living, sports and recreation and quality
of life subscales (P < 0.001). Histological evaluation of
five patients showed a homogeneous hyaline-like cartil-
age repair tissue.No complications related to PRP were noted in any of
the studies described above during their follow-up.
Degenerative joint diseases
Level IV case series
Among the case reports illustrated in Table 6 [92-99],
Wang-Saegusa and colleagues [99] reported the largest
case series of knee OA treated with P-PRP intra-articular
injections. A total of 808 patients were treated and 261
were evaluated after strictly applying the inclusion and
exclusion criteria. At the end of 6 months, pain was sig-
nificantly reduced while knee function and quality of life
were improved, without occurrence of adverse events.
The authors concluded that P-PRP injections had local,
effective and temporal effects reducing pain and restor-
ing function. However, the lack of a placebo group or
conservatively managed control undermined the con-
clusions of these studies.
Level III retrospective comparative studies
In a retrospective cohort of 30 patients sustaining
chronic knee pain, the efficacy of PRP injections was
compared with the more common, well-recognized HA
treatment [100]. Patients received three intra-articular
injections of inactivated double-spun PRP or HA every
3 weeks and were followed for 6 months after the final
injections. Both groups showed significant improvement
in IKDC, Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) and Lequesne Index,
but the PRP-treated patients exhibited better results at
6 months than the HA-treated patients. Sánchez and
colleagues [101] reported a similar cohort study to com-
pare the therapeutic effect of P-PRP and HA for treat-
ment of knee OA. Each group included 30 patients
matched according to their age, sex, body mass index
and OA severity on radiography. Results were only con-
sidered successful when a reduction of at least 40% from
baseline in WOMAC pain scores occurred. In the PRP
group, the success rate reached 33.4% at 5 weeks com-
pared to only 10% in the HA group (P = 0.004). In
addition, with respect to HA treatment, P-PRP injections
significantly reduced the physical function subscale and
the overall WOMAC (P = 0.043, P = 0.010, respectively)
in favor of PRP treatment.
Level II prospective comparative studies or lesser quality
randomized controlled trials
Two recent prospective cohort studies further confirmed
the superiority of PRP over HA injections for treatment
of knee OA [102,103]. Spaková and colleagues [102] re-
ported 120 knee OA patients who were randomly
treated with three injections of L-PRP or HA, one per
week. At 3 and 6 months follow-up, better results in
WOMAC and Numeric Rating Scale were obtained in
Table 6 Summary of clinical studies of platelet-rich plasma for treatment of degenerative cartilage lesions
Level of
evidencea
Patient number
(age/range)
Intervention Follow-up Outcome Adverse effects Reference
Level IV 14 (18–87 years) 3 L-PRP injections every
4 weeks
12 m Significant and linear
improvement in KOOS.
Pain reduced after movement
and at rest
Modest pain persisting
for days
[92]
Level IV 17 (30–70 years) Single PRP injection 12 m Pain decreased, whereas
function improved. MRI showed
no worsening in 12 of 15 knees
Unreported [93]
Level IV 27 (18–81 years) 3 weekly L-PRP injections 6 m Substantial pain reduction after
1st injection and further improved
at 6 months. WOMAC improved
No [94]
Level IV 40 (33–84 years) 3 weekly P-PRP injections 6 m Pain and disability subscores
were significantly reduced
Transient sensation of
hip heaviness
[95]
Level IV 50 (32–60 years) 2 L-PRP injections every month 12 m IKDC and KOOS improved;
all returned to previous activities
Unreported [96]
Level IV 91 (24–82 years) 3 injections of double-spun
PRP activated by CaCl2 every
3 weeks
12 m, 24 m Pain decreased and knee
function improved, especially
in younger patients at 12 months.
The improvements decreased at
24 months, but still better than
the basal evaluation
Mild pain persisting for
days
[97,98]
Level IV 261 (mean 48 years) 3 injections of CaCl2-activated
P-PRP every 2 weeks
6 m Significant differences in VAS,
SF-36, WOMAC and Lequesne index
No [99]
Level III 30 (36–76 years) 3 injections of double-spun
PRP inactivated PRP or HA
every 3 weeks
6 m Both improved in IKDC, WOMAC
and Lequesne index, but PRP
exhibited better scores
Pain, swelling, but
resolved in days
[100]
Level III 60 (61 years in HA,
64 years in PRP)
3 weekly injections of
CaCl2-activated P-PRP or HA
5 w 33.4% patients in PRP group and
10% in HA achieved at least 40%
pain reduction. Disability reduced
more in PRP group than HA
Mild self-limiting pain
and effusion in both
groups
[101]
Level II 120 (19–77 years) 3 weekly L-PRP or HA injections 6 m Better results in WOMAC and
NRS in PRP than HA
Temporary mild
worsening of pain
[102]
Level II 150 (26–81 years) 3 injections double-spun PRP
or HA every 2 weeks
6 m Higher IKDC but lower VAS pain
scores than HA, especially in
younger patients
No [103]
Level II 32 (18–60 years) 3 injections of CaCl2-activated
P-PRP or HA every 2 weeks
7 m Higher AOFAS but lower
VAS pain scores than HA
Mild pain, but
self-resolved
[104]
Level I 78 (33–80 years) Single or twice leukocyte-filtered
PRP injection, or single saline
injection
6 m WOMAC improved after
PRP injection, whereas worsened
after saline infiltration
Self-resolved nausea
and dizziness
[105]
Level I 120 (31–90 years) 4 weekly injections of inactivated
P-PRP or HA
6 m Significantly better clinical
outcome and lower WOMAC
scores than HA
None observed [106]
Level I 176 (41–74 years) 3 weekly injections of
CaCl2-activated P-PRP or HA
6 m 14.1% more patients reduced
pain at least 50% in PRP group,
with a significant difference
Mild, evenly in
2 groups
[107]
Level I 96 (50–84 years) 3 injections of CaCl2-activated
P-PRP every 2 weeks, or single
HA injection
48 w Significantly more efficient in
reducing pain, stiffness and
improving physical function
than HA
Mild, evenly in
2 groups
[108]
Level I 109 (18–80 years) 3 weekly injections of
double-spun PRP releasate
after freezing and thawing or HA
12 m No significant difference in
all scores. Only a trend favoring
PRP in patients with early OA
Mild pain and effusion [109]
aAccording to [84,85]. AOFAS, American Orthopaedic Foot and Ankle Society; HA, hyaluronic acid; IKDC, International Knee Documentation Committee; KOOS,
Knee injury and Osteoarthritis Outcome Score; L-PRP, leukocyte- and platelet-rich plasma; m, months; MRI, magnetic resonance imaging; NRS, Numeric Rating
Scale; P-PRP, pure platelet-rich plasma; PRP, platelet-rich plasma; SF, short form; VAS, visual analogue scale; w, weeks; WOMAC, Western Ontario and McMaster
Universities Osteoarthritis Index.
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150 patients suffering knee cartilage degenerative le-
sions, who were divided evenly into three groups [103].
These three homogeneous groups received three intra-
articular injections of double-spun PRP, low-molecular-
weight HA or high-molecular-weight HA. At 6 months
follow-up, the best results in terms of IKDC, visual
analogue scale and patient satisfaction were achieved in
the PRP group (P < 0.005), in particular for the younger
patients affected by cartilage lesions or early OA.
In an RCT comparing P-PRP and HA treatment in a
total of 32 patients suffering talar osteochondral lesions
[104], the mean AOFAS score was significantly improved
from 68 and 66 before injection to 92 and 78 after
28 weeks in P-PRP and HA groups (P < 0.0001), respect-
ively, favoring P-PRP treatment (P < 0.05). Better results
for the visual analogue scale and other subjective function
scores were also noted in the P-PRP group (P < 0.01).
Level I high-quality randomized controlled trials
A recent RCT compared PRP with placebo for the treat-
ment of knee OA [105]. Seventy-eight patients (156 knees)
were randomly divided into three groups. Group A re-
ceived a single injection of P-PRP, group B received two
injections of P-PRP 3 weeks apart, and group C received a
single saline infiltration. After 6 months, all the subscores
in WOMAC improved in groups A and B, but worsened
in group C. These results support the short-term effective-
ness of P-PRP injections over placebo for relieving pain
and improving knee function.
The efficacy of PRP in the treatment of OA was also
compared with HA administration. Cerza and colleagues
[106] reported on 120 gonarthrosis patients undergoing
4 randomized intra-articular injections of P-PRP or HA.
Patients in two groups were matched in terms of age,
gender, severity of knee arthrosis and pre-treatment
WOMAC scores. All patients were WOMAC evaluated
before the infiltration and at 4, 12 and 24 weeks after
the first injection. While post-treatment WOMAC
scores in both groups significantly improved compared
to before the infiltration, the improvement was more
significant in the P-PRP-treated group than the HA
group at each time point. In addition, the trend contin-
ued during the 24-week follow-up in the P-PRP group,
but began to attenuate at 4 weeks in the HA group.
These results indicated that P-PRP had a stronger and
longer effect on the attenuation of OA with respect to
HA treatment. In a multicenter, double-blind RCT, a
total of 176 patients with symptomatic knee OA were
randomly assigned to receive P-PRP or HA infiltrations
[107]. The groups were well balanced for age, gender,
body mass index, percentage of patients with primary
arthritis, daily consumption of analgesics, radiographic
grade, and WOMAC and Lequesne scores. The primaryoutcome measure was a 50% decrease in knee pain from
baseline to week 24; according to this, the rate of re-
sponse was 14.1% higher in P-PRP-treated patients com-
pared to the HA-treated group. Regarding the secondary
outcome measures assessing pain, stiffness and physical
function, PRP also yielded better results than HA, albeit
not reaching significance. Another recent RCT con-
firmed the superiority of P-PRP over HA in the allevi-
ation of knee pain and stiffness and the improvement of
physical function at both 24 and 48 weeks [108].
On the other hand, a single-center, double blind RCT
including 109 matched patients demonstrated that PRP
treatment did not lead to statistically significant differ-
ences in all scores evaluated with respect to HA injections
at 12-month follow-up [109]. Further analysis showed a
tendency favoring PRP in patients with less degenerated
joints at 6 months and 12 months, although no significant
difference was reached (P = 0.08 and P = 0.07, respect-
ively). However, unlike the aforementioned RCTs, which
used fresh P-PRP, this trial prepared PRP manually by
double-spinning followed by freezing and thawing. Al-
though the accurate concentration of leukocytes was
unreported, it was estimated that this preparation con-
centrated leukocytes together with platelets and the final
product was likely to contain much higher levels of pro-
inflammatory signaling cytokines than P-PRP [46,110].
The unfavorable effect of concentrated leukocytes in
PRP is also reflected in post-injection reactions. After
intra-articular P-PRP injections, undetectable or only mild,
self-resolved adverse events were observed, comparable to
that observed with HA administration [106-108], but the
double-spun PRP induced a significantly higher rate of
pain reaction than the HA treatment (P = 0.039) [109]. A
RCT comparing single- and double-spun PRP confirmed
that the latter produced more pain and swelling reaction
than the former, in which leukocytes were less concen-
trated [111].
Conclusion
Research findings derived from basic and preclinical stud-
ies and from clinical trials collectively suggest that PRP is a
promising treatment for cartilage injuries and relieving
symptoms owing to its three known biological properties.
Firstly, PRP has an anabolic effect on chondrocytes, MSCs
and synoviocytes with resultant increases in cell prolifera-
tion, cartilaginous ECM accumulation, and HA secretion.
Secondly, PRP may act as a bioactive cell scaffold to fill de-
fects and enhance cartilage regeneration. Thirdly, PRP has
the potential to inhibit inflammation and alleviate OA
symptoms with a clinically acceptable safety profile. Al-
though the majority of published evidence has favored PRP
over HA for treatment of OA, PRP therapy remains unpre-
dictable owing to the significant heterogeneity among stud-
ies and the variability in PRP preparations. Future studies
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tween specific components of PRP and major patho-
genic mechanisms.
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